Streptococcus pneumoniae Serotype 12F-CC4846 and Invasive Pneumococcal Disease after Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Japan, 2015–2017
To prevent invasive pneumococcal disease (IPD), pneumococcal conjugate vaccines (PCVs) have been implemented in many countries; however, many cases of IPD still occur and can be attributable to nonvaccine serotypes of Streptococcus pneumoniae. In Japan, the number of IPD cases attributable to seroty...
| Published in: | Emerging Infectious Diseases |
|---|---|
| Main Authors: | Satoshi Nakano, Takao Fujisawa, Yutaka Ito, Bin Chang, Yasufumi Matsumura, Masaki Yamamoto, Shigeru Suga, Makoto Ohnishi, Miki Nagao |
| Format: | Article |
| Language: | English |
| Published: |
Centers for Disease Control and Prevention
2020-11-01
|
| Subjects: | |
| Online Access: | https://wwwnc.cdc.gov/eid/article/26/11/20-0087_article |
Similar Items
EXPERIENCE OF APPLICATION AND SAFETY ASSESSMENT OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN UNDER-5 CHILDREN
by: M. V. Fedoseenko, et al.
Published: (2014-09-01)
by: M. V. Fedoseenko, et al.
Published: (2014-09-01)
A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
by: Thundon Ngamprasertchai, et al.
Published: (2023-06-01)
by: Thundon Ngamprasertchai, et al.
Published: (2023-06-01)
Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
by: Germaine Hanquet, et al.
Published: (2022-01-01)
by: Germaine Hanquet, et al.
Published: (2022-01-01)
Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions
by: Jeffrey Vietri, et al.
Published: (2020-01-01)
by: Jeffrey Vietri, et al.
Published: (2020-01-01)
Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States
by: John M. McLaughlin, et al.
Published: (2019-04-01)
by: John M. McLaughlin, et al.
Published: (2019-04-01)
Changes in Childhood Pneumonia Hospitalizations by Race and Sex Associated with Pneumococcal Conjugate Vaccines
by: Andrew D. Wiese, et al.
Published: (2016-06-01)
by: Andrew D. Wiese, et al.
Published: (2016-06-01)
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered in a prime-boost regimen among Chinese infants: a randomized, double blind phase III clinical trial
by: Wenjuan Wang, et al.
Published: (2022-01-01)
by: Wenjuan Wang, et al.
Published: (2022-01-01)
Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18–49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors
by: Laura L. Hammitt, et al.
Published: (2023-01-01)
by: Laura L. Hammitt, et al.
Published: (2023-01-01)
Pneumococcal Serotype Evolution and Burden in European Adults in the Last Decade: A Systematic Review
by: Rita Teixeira, et al.
Published: (2023-05-01)
by: Rita Teixeira, et al.
Published: (2023-05-01)
Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine (PCV20) to prevent pneumococcal disease in the Greek pediatric population
by: Charalampos Tzanetakos, et al.
Published: (2025-12-01)
by: Charalampos Tzanetakos, et al.
Published: (2025-12-01)
Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
by: Kristiana Alexandrova Nikolova, et al.
Published: (2021-10-01)
by: Kristiana Alexandrova Nikolova, et al.
Published: (2021-10-01)
Surveillance of adverse events following immunization of 13-valent pneumococcal conjugate vaccine among infants, in Zhejiang province, China
by: Yu Hu, et al.
Published: (2022-01-01)
by: Yu Hu, et al.
Published: (2022-01-01)
Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged < 5 Years: A Prospective Study
by: Sergi Hernández, et al.
Published: (2020-07-01)
by: Sergi Hernández, et al.
Published: (2020-07-01)
Analysis of 13-valent pneumococcal polysaccharide conjugate vaccine among children born in Hangzhou from 2017 to 2021
by: Xinren Che, et al.
Published: (2023-05-01)
by: Xinren Che, et al.
Published: (2023-05-01)
Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus “no vaccination” and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine
by: Miguel Gouveia, et al.
Published: (2019-04-01)
by: Miguel Gouveia, et al.
Published: (2019-04-01)
The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities
by: Yan Li, et al.
Published: (2021-11-01)
by: Yan Li, et al.
Published: (2021-11-01)
Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands
by: Michele Wilson, et al.
Published: (2023-06-01)
by: Michele Wilson, et al.
Published: (2023-06-01)
Cost-Effectiveness Analysis of the South African Infant National Immunization Program for the Prevention of Pneumococcal Disease
by: Liping Huang, et al.
Published: (2023-02-01)
by: Liping Huang, et al.
Published: (2023-02-01)
Historical Population-Level Impact of Infant 13-Valent Pneumococcal Conjugate Vaccine (PCV13) National Immunization Programs on Invasive Pneumococcal Disease in Australia, Canada, England and Wales, Israel, and the United States
by: Johnna Perdrizet, et al.
Published: (2023-04-01)
by: Johnna Perdrizet, et al.
Published: (2023-04-01)
Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQ
by: Starla Hayward, et al.
Published: (2016-04-01)
by: Starla Hayward, et al.
Published: (2016-04-01)
Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
by: Mikkelsen Malene B, et al.
Published: (2023-08-01)
by: Mikkelsen Malene B, et al.
Published: (2023-08-01)
Decrease of Pneumococcal Community-Acquired Pneumonia Hospitalization and Associated Complications in Children after the Implementation of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Taiwan
by: Ching-Fen Shen, et al.
Published: (2021-09-01)
by: Ching-Fen Shen, et al.
Published: (2021-09-01)
Empyema due to Streptococcus Pneumoniae Serotype 9V in a Child Immunized with 13-Valent Conjugated Pneumococcal Vaccine
by: Murat Sütçü, et al.
Published: (2017-02-01)
by: Murat Sütçü, et al.
Published: (2017-02-01)
PHARMACOECONOMIC ASSESSMENT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN IMMUNIZATION OF CHILDREN IN RUSSIAN FEDERATION
by: A. V. Rudakova, et al.
Published: (2014-01-01)
by: A. V. Rudakova, et al.
Published: (2014-01-01)
Clinical and Bacteriological Analysis of Pediatric Pneumococcal Meningitis after 13-Valent Pneumococcal Conjugate Vaccine Introduction in Japan
by: Erika Kurihara, et al.
Published: (2022-04-01)
by: Erika Kurihara, et al.
Published: (2022-04-01)
The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C
by: Yaru Shi, et al.
Published: (2023-08-01)
by: Yaru Shi, et al.
Published: (2023-08-01)
Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
by: Beate Schmoele-Thoma, et al.
Published: (2019-03-01)
by: Beate Schmoele-Thoma, et al.
Published: (2019-03-01)
Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea
by: Min-Joo Choi, et al.
Published: (2018-08-01)
by: Min-Joo Choi, et al.
Published: (2018-08-01)
Pharmacoeconomic aspects of vaccination against Pneumococcal Infection in Russia
by: A. V. Rudakova, et al.
Published: (2014-09-01)
by: A. V. Rudakova, et al.
Published: (2014-09-01)
Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10- or 13-Valent) Versus No Vaccination for a National Immunization Program in Tunisia or Algeria
by: Sarah J. Pugh, et al.
Published: (2018-12-01)
by: Sarah J. Pugh, et al.
Published: (2018-12-01)
Serotype epidemiology and case-fatality risk of invasive pneumococcal disease: a nationwide population study from Switzerland, 2012–2022
by: Werner C. Albrich, et al.
Published: (2025-12-01)
by: Werner C. Albrich, et al.
Published: (2025-12-01)
Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis
by: Sarah Pugh, et al.
Published: (2020-02-01)
by: Sarah Pugh, et al.
Published: (2020-02-01)
Pneumococcal serotype-specific IgG and opsonophagocytic activity in young Japanese patients with asplenia
by: Kenichi Takeshita, et al.
Published: (2021-10-01)
by: Kenichi Takeshita, et al.
Published: (2021-10-01)
The 13-valent pneumococcal conjugate vaccine (PCV13) does not appear to provide much protection on combined invasive disease due to the six PCV13 non-PCV7 serotypes 1, 3, 5, 6A, 7F, and 19A in Kuwait during 2010–2019
by: Eiman Mokaddas, et al.
Published: (2021-11-01)
by: Eiman Mokaddas, et al.
Published: (2021-11-01)
Analysis of Morbidity Dynamics and Factors Influencing the Development of Pneumococcal Infections among the Adult Population of the Sakha Republic (Yakutia)
by: A. N. Argunova, et al.
Published: (2018-09-01)
by: A. N. Argunova, et al.
Published: (2018-09-01)
Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults
by: Nobuhiro Asai, et al.
Published: (2021-11-01)
by: Nobuhiro Asai, et al.
Published: (2021-11-01)
Immunogenicity, safety and tolerability of 15-valent pneumococcal conjugate vaccine (V114) compared to 13-valent pneumococcal conjugate vaccine (PCV-13) in healthy infants: A systematic review and meta-analysis
by: Muhammad Zain Ul Haq, et al.
Published: (2025-06-01)
by: Muhammad Zain Ul Haq, et al.
Published: (2025-06-01)
Immunogenicity of pneumococcal vaccination in HIV infected individuals: A systematic review and meta-analysis
by: Hannah M.Garcia Garrido, et al.
Published: (2020-12-01)
by: Hannah M.Garcia Garrido, et al.
Published: (2020-12-01)
Cost-effectiveness analysis of routine 13-valent pneumococcal conjugate vaccinations in Chinese infants
by: Hua Zhou, et al.
Published: (2018-06-01)
by: Hua Zhou, et al.
Published: (2018-06-01)
Safety and immunogenicity of a 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A Phase I study (V114-028)
by: Yasunori Ishihara, et al.
Published: (2023-01-01)
by: Yasunori Ishihara, et al.
Published: (2023-01-01)
Similar Items
-
EXPERIENCE OF APPLICATION AND SAFETY ASSESSMENT OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN UNDER-5 CHILDREN
by: M. V. Fedoseenko, et al.
Published: (2014-09-01) -
A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
by: Thundon Ngamprasertchai, et al.
Published: (2023-06-01) -
Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
by: Germaine Hanquet, et al.
Published: (2022-01-01) -
Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions
by: Jeffrey Vietri, et al.
Published: (2020-01-01) -
Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States
by: John M. McLaughlin, et al.
Published: (2019-04-01)
